1.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: ECOG-3598, E3598, NCT00004859
|
|
2.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-00-C-0080, NCI-T99-0053, T99-0053, NCT00020085
|
|
3.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: SWOG-S9922, NCT00005834, S9922
|
|
4.
|
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: ECOG-2898, NCT00005966, E2898
|
|
5.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 65
Sponsor: Other
Protocol IDs: CKTO-2001-02, HOVON-50MM, EU-20133, HOVON-CKVO-2001-02, NCT00028886
|
|
6.
|
Phase: Phase III
Type: Treatment
Status: Completed
Age: Over 18
Sponsor: NCI
Protocol IDs: RTOG-BR-0118, RTOG-DEV-1006, NCT00033254
|
|
7.
|
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: E-E1A00, NCT00033332, E1A00
|
|
8.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: Not specified
Sponsor: NCI
Protocol IDs: GOG-0198, NCT00041080
|
|
9.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: Over 18
Sponsor: Other
Protocol IDs: LLCG-STUDY-12, EU-20207, ISRCTN16174527, NCT00061919
|
|
10.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: THAL-MM-003, NCT00057564
|
|
11.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 75
Sponsor: Other
Protocol IDs: UARK 2003-33, NCT00081939
|
|
12.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: ECOG-E4A03, E4A03, NCT00098475
|
|
13.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR004579, NCT00097981
|
|
14.
|
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: UARK 2005-01, NCT00111748
|
|
15.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: MCC-13043, USFIRB#100842, NCT00215943
|
|
16.
|
Phase: Phase III
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: Other
Protocol IDs: NMSG #12, NFR 90000288, NCT00218855
|
|
17.
|
Phase: Phase III
Type: Treatment
Status: Completed
Age: Under 60
Sponsor: Other
Protocol IDs: MM01, NCT00207805
|
|
18.
|
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MAYO-MC0289, MAYO-IRB-421-03, NCT00432458
|
|
19.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: THA PH INT 2005 CL 001, NCT00452569
|
|
20.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NYU-9635, NCI-G98-1419
|
|
21.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-99103, NCI-G00-1786, NCT00005815
|
|
22.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MDA-ID-00087, NCT00082693
|
|
23.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: UARK 98-023, NCT00081757
|
|
24.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2003-25, NCT00113919
|
|
25.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-95-C-0178L, NCI-CPB-372, NCI-T95-0038N, T95-0038
|
